GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.26 USD
+0.01 (2.92%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $0.26 0.00 (1.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
GLYC 0.26 +0.01(2.92%)
Will GLYC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GLYC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GLYC
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
GLYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
Are Medical Stocks Lagging Axonics (AXNX) This Year?
Other News for GLYC
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
Analysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC), Establishment Labs Holdings (ESTA) and DocGo (DCGO)
H.C. Wainwright Sticks to Their Hold Rating for GlycoMimetics (GLYC)
GlycoMimetics Reports Phase 3 Uproleselan Trial Success
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)